Antibody evolution immunogens
US-2015366961-A1 · Dec 24, 2015 · US
Recombinant viral vectors
US9610346B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9610346-B2 |
| Application number | US-201313792106-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 10, 2013 |
| Priority date | Mar 23, 2012 |
| Publication date | Apr 4, 2017 |
| Grant date | Apr 4, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A recombinant vesicular stomatitis virus (VSV) vector encoding and expressing a membrane-anchored HIV Env immunogen and a natural VSV attachment protein (G) (EnvG) chimera, wherein the genes in the VSV vector are arranged sequentially in the order 3′-N-P-M-EnvG-L-G-5′. 2. The vector of claim 1 , wherein the G gene is transferred to a 5′-terminal position in the negative-sense RNA genome of the recombinant VSV vector. 3. The vector of claim 1 , wherein the vector comprises a sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 6. 4. The vector of claim 1 , wherein the vector expresses a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 4. 5. The vector of claim 1 , wherein the EnvG chimera comprises a truncated cytoplasmic tail. 6. The vector of claim 2 , wherein the EnvG chimera comprises a truncated cytoplasmic tail. 7. A method of producing an immune response or eliciting an immune response comprising administering to a mammal the vector of claim 1 .
Assignees
Inventors
Classifications
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
viral genome or elements thereof as genetic vector · CPC title
- A61K39/21Primary
Retroviridae, e.g. equine infectious anemia virus · CPC title
Viral antigens · CPC title
expressing foreign proteins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9610346B2 cover?
- The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative
- What technology area does this patent fall under?
- Primary CPC classification A61K39/21. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).